港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維立志博-B

58.000

-4.450-7.13%

成交量：534.04萬

成交額：3.16億

市值：115.42億

市盈率：-41.36

高：62.750

開：61.300

低：56.450

收：62.450

52周最高：97.500

52周最低：44.720

股本：1.99億

香港流通股本：1.98億

量比：41.82

換手率：2.70%

股息：- -

股息率：- -

每股收益(LYR):-1.402

淨資產收益率：-27.61%

總資產收益率：-9.92%

市淨率：7.87

市盈率(LYR):-41.36

市銷率: 56.19

資料載入中...

總覽公司新聞公告

維立志博(09887.HK)首席執行官自願延長禁售期至明年1月

阿斯达克财经

維立志博-B首席執行官自願延長7,874,617股H股禁售期至2027年1月24日

維立志博-B(09887.HK)聯合創始人康小強自願延長禁售期彰顯長期發展信心

昆藥集團：擬減持不超244.3022萬股維立志博股票

每日经济新闻

一周港股牛熊榜 | 真健康醫療-B受手術機器人題材催化爆升74%，卓越睿新牽手阿里雲漲逾40%；德適-B高估值回調近37%，鈞達股份預虧拖累跌逾34%

老虎资讯综合

港股異動 | 維立志博-B(09887)再升逾11% 近3日股價累升逾三成多項研究成果入選2026 ESMO

維立志博-B盤中升逾15% 核心管線LBL-024被納入優先審評審批程序

港股異動 | 維立志博-B(09887.HK)升逾13% ESMO多項研究成果入選核心管線LBL-024被納入優先審評

維立志博－Ｂ(09887)股價上升5.042%，現價港幣$62.5

阿斯达克财经

維立志博-B（09887）六項研究成果入選2026年ESMO年會兩項獲最高規格口頭報告

維立志博-B(09887)：多項研究成果入選2026 ESMO

Gate 港股高彈性標的活躍，維立志博-B大漲近 30% 領升漲幅榜

維立志博-B午前升逾27% 維利信®上市申請納入優先審評

港股異動 | 維立志博-B(09887.HK)升逾26% 維利信®上市申請納入優先審評商業化進程全面提速

維立志博－Ｂ(09887)股價上升5.068%，現價港幣$52.45

阿斯达克财经

維立志博-B旗下Opamtistomig用於晚期上皮性腫瘤的BLA獲中國NMPA授予優先審評資格

優先審評資格授予PD-L1/4-1BB雙特異性抗體Opamtistomig，加速商業化進程並應對上皮樣肉瘤未滿足的臨床需求

港股異動 | 維立志博-B(09887.HK)升逾5% 維利信™獲納入優先審評審批程序用於治療晚期肺外神經內分泌癌

維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲納入優先審評審批程序用於治療晚期肺外神經內分泌癌

維立志博-B獲NMPA優先審評資格　PD-L1/4-1BB雙抗維利信™衝刺EP-NEC首款上市藥物

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09887/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"維立志博-B","latestPrice":58,"timestamp":1785117702238,"preClose":62.45,"halted":0,"volume":5340400,"delay":0,"changeRate":-0.07125700560448363,"floatShares":198000000,"shares":199000000,"eps":-1.4019550505406952,"marketStatus":"交易中","change":-4.45,"latestTime":"07-27 10:01:45","open":61.3,"high":62.75,"low":56.45,"amount":316397937,"amplitude":0.100881,"askPrice":58.15,"askSize":22400,"bidPrice":58,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-1.3637199127986763,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1785124800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":62.45,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":41.819035,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.402238,"volumeRatio":41.819035,"shares":199000000,"dividePrice":0,"high":62.75,"amplitude":0.100881,"preClose":62.45,"low":56.45,"week52Low":44.72,"pbRate":"7.87","psRate":"56.19","week52High":97.5,"institutionHeld":0,"latestPrice":58,"committee":-0.473684,"eps":-1.402237758398946,"divideRate":0,"volume":5340400,"delay":0,"ttmEps":-1.3639949104426112,"open":61.3,"prevYearClose":51,"prevWeekClose":62.45,"prevMonthClose":49.32,"prevQuarterClose":49.32,"fiveDayClose":64.45,"twentyDayClose":49.58,"sixtyDayClose":81.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-07-24","current":-45.804107,"percent":0.258197,"low":-76.458084,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"high":-30.202688,"avg":-41.824579,"sd":10.124459,"marketCap":12420792910},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910}],"updateTime":1785101828994},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654109588","title":"維立志博(09887.HK)首席執行官自願延長禁售期至明年1月","url":"https://stock-news.laohu8.com/highlight/detail?id=2654109588","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654109588?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 09:46","pubTimestamp":1785116760,"startTime":"0","endTime":"0","summary":"维立志博(09887.HK) 公布，集团联合创始人、董事长、执行董事、首席执行官兼总经理康小强自愿延长其直接持有的787.46万股H股的禁售期，由原定的2026年7月24日延长额外6个月至2027年1月24日。于经延长禁售期内，康小强不会以任何方式直接或间接处置或以其他方式削减其直接持有的该等股份。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-07-24 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250721150113116_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250721150113116_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1534972/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1534972/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101511326","title":"維立志博-B首席執行官自願延長7,874,617股H股禁售期至2027年1月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=1101511326","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101511326?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 18:21","pubTimestamp":1784888494,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司7月24日晚间发布自愿公告称，公司联合创始人、董事长、执行董事、首席执行官兼总经理康小强博士已提交书面承诺，将其直接持有的全部7,874,617股H股禁售期在原基础上再延长六个月。在此期间，康小强博士不得出售、质押、转让或以其他方式处置上述股份。公司表示，延期承诺体现了康小强博士对公司长期价值和行业前景的信心。公告日期为2026年7月24日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653085552","title":"維立志博-B(09887.HK)聯合創始人康小強自願延長禁售期 彰顯長期發展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2653085552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653085552?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 18:03","pubTimestamp":1784887403,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653108307","title":"昆藥集團：擬減持不超244.3022萬股維立志博股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2653108307","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653108307?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 17:48","pubTimestamp":1784886520,"startTime":"0","endTime":"0","summary":"【昆药集团：拟减持不超244.3022万股维立志博股票】7月24日，昆药集团公告称，为进一步强化主业、优化资产结构，公司拟通过集中竞价、大宗交易等方式择机减持不超过244.3022万股维立志博股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607243820568626.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607243820568626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK1161","09887","HK0000500386.USD","HK0000252152.HKD","BK0239","600422","BK0060","BK0188","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168059671","title":"一周港股牛熊榜 | 真健康醫療-B受手術機器人題材催化爆升74%，卓越睿新牽手阿里雲漲逾40%；德適-B高估值回調近37%，鈞達股份預虧拖累跌逾34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168059671","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168059671?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 17:24","pubTimestamp":1784280294,"startTime":"0","endTime":"0","summary":"总结全周（7月13日-7月17日），恒生指数涨387.12点或1.6%，恒生科技指数跌98.49点或2.09%。本周涨幅居前个股中，真健康医疗-B受手术机器人稀缺性及高端医疗器械政策催化，累计上涨74%；卓越睿新与阿里云合作推进AI教学及科研场景落地，本周上涨40.03%；维立志博-B因六项研究入选ESMO、核心管线进入优先审评，累计上涨29.21%。跌幅方面，德适-B在高估值及持续亏损压力下累计下跌36.94%；钧达股份预告上半年最高亏损2.7亿元，累计下跌34.83%；建滔积层板在PCB涨价线高位回落下累计下跌33.15%。","market":"hk","thumbnail":"https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb1639b5fc4982ccb82111d6af456d9b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02697","02889","06127","02526","09887","02687","BK4588","03277","02865","00148","01888"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651432957","title":"港股異動 | 維立志博-B(09887)再升逾11% 近3日股價累升逾三成 多項研究成果入選2026 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651432957","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651432957?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 14:25","pubTimestamp":1784096755,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B再涨超11%，近三个交易日股价累涨超三成。截至发稿，涨11.45%，报67.15港元，成交额1.66亿港元。消息面上，近日，维立志博公布了2026年ESMO入选结果，已确认六项最新研究成果入选，其中最高规格口头报告两项，9月预计还有LBA入选。公司表示，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","HK0000252152.HKD","BK4588","BK4585","HK0000500386.USD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651129589","title":"維立志博-B盤中升逾15% 核心管線LBL-024被納入優先審評審批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2651129589","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651129589?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 11:41","pubTimestamp":1784000460,"startTime":"0","endTime":"0","summary":"　　维立志博-B早盘一度涨超15%，截至发稿，股价上涨6.39%，现报63.30港元，成交额1.67亿港元。　　7月10日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信单药治疗晚期经治肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心批准纳入优先审评审批程序。公司指，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。与此同时，维立志博正积极推进上市前的各项商业化准备工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-14/doc-inihtvuh8558402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651125132","title":"港股異動 | 維立志博-B(09887.HK)升逾13% ESMO多項研究成果入選 核心管線LBL-024被納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2651125132","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651125132?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 10:23","pubTimestamp":1783995804,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651259921","title":"維立志博－Ｂ(09887)股價上升5.042%，現價港幣$62.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2651259921","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651259921?lang=zh_tw&edition=fundamental","pubTime":"2026-07-14 10:10","pubTimestamp":1783995000,"startTime":"0","endTime":"0","summary":"[上升股]维立志博－Ｂ(09887) 股价在上午10:09比前收市价上升5.042%，现股价为港币$62.5。至目前为止，今日最高价为$62.5，而最低价为$55.9。总成交量为85.77万股，总成交金额为港币$5.048千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2607141269/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2607141269/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121474067","title":"維立志博-B（09887）六項研究成果入選2026年ESMO年會 兩項獲最高規格口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=1121474067","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121474067?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 16:42","pubTimestamp":1783932120,"startTime":"0","endTime":"0","summary":"2026年7月13日，维立志博-B发布自愿公告称，其六项最新研究成果已获欧洲肿瘤内科学会年会接收，其中两项被选为最高规格的“优选口头报告”，其余四项将进行壁报展示。此外，公司同获“最新突破摘要”资格，并计划于2026年9月提交完整摘要。ESMO 2026年会将于2026年10月23日至27日在西班牙马德里举行。公告同时回顾，公司此前披露的维利信一线非小细胞肺癌研究，已入选2026年世界肺癌大会口头报告，相关摘要预计于2026年8月19日在WCLC官网公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194274","title":"維立志博-B(09887)：多項研究成果入選2026 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651194274?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 16:38","pubTimestamp":1783931924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，其六项最新研究成果入选2026年欧洲肿瘤内科学会年会。此外，公司已获授最新突破摘要资格，并将于2026年9月提交完整LBA。LBA则为针对被视为具有突破性且有望改变临床实践的最新临床研究进展而设的专门类别。公司此前亦公布，维利信用于治疗一线非小细胞肺癌的研究已入选于2026年9月举行的世界肺癌大会上进行口头报告。摘要全文预期将于2026年8月19日在WCLC官方网站上发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651199676","title":"Gate 港股高彈性標的活躍，維立志博-B大漲近 30% 領升漲幅榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2651199676","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651199676?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 15:15","pubTimestamp":1783926923,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，港股市场整体呈现震荡分化，部分高弹性标的逆势走强。Gate 平台港股涨幅榜前三分别为：维立志博-B 大涨 29.90%，现报 HK$64.85；广联科技控股上涨 21.70%，现报 HK$4.99；中国华君上涨 20.66%，现报 HK$1.46。\n\n ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2276190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","VXUS","BK1161","09887","HK0000500386.USD","BK4588","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651816037","title":"維立志博-B午前升逾27% 維利信®上市申請納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2651816037","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651816037?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 11:27","pubTimestamp":1783913220,"startTime":"0","endTime":"0","summary":"　　维立志博-B午前涨超27%，截至发稿，股价上涨27.40%，现报63.60港元，成交额2.02亿港元。　　7月10日，维立志博宣布，公司自主研发的PD-L1/4-1BB双特异性抗体维利信单药治疗晚期经治肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心批准纳入优先审评审批程序。　　公司指，这一里程碑标志着维利信的商业化时间表正式锁定，获批上市时间明确可期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9119990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000252160.HKD","HK0000252152.HKD","IPOS","BK1161","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651167228","title":"港股異動 | 維立志博-B(09887.HK)升逾26% 維利信®上市申請納入優先審評 商業化進程全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2651167228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651167228?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 11:02","pubTimestamp":1783911745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651944162","title":"維立志博－Ｂ(09887)股價上升5.068%，現價港幣$52.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2651944162","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651944162?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 09:35","pubTimestamp":1783906500,"startTime":"0","endTime":"0","summary":"[上升股]维立志博－Ｂ(09887) 股价在上午09:35比前收市价上升5.068%，现股价为港币$52.45。至目前为止，今日最高价为$52.45，而最低价为$49.92。总成交量为4.63万股，总成交金额为港币$238.265万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260713412/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260713412/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131778575","title":"維立志博-B旗下Opamtistomig用於晚期上皮性腫瘤的BLA獲中國NMPA授予優先審評資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1131778575","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131778575?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673720,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技有限公司宣布，其用于治疗晚期上皮性肿瘤的新药Opamtistomig的生物制品许可申请，已获得中国国家药品监督管理局授予优先审评资格。此举标志着该候选药物在加速审批通道上迈出了关键一步，有望更早惠及患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189644529","title":"優先審評資格授予PD-L1/4-1BB雙特異性抗體Opamtistomig，加速商業化進程並應對上皮樣肉瘤未滿足的臨床需求","url":"https://stock-news.laohu8.com/highlight/detail?id=1189644529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189644529?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673720,"startTime":"0","endTime":"0","summary":"PD-L1/4-1BB双特异性抗体Opamtistomig获得优先审评资格，此举将显著加速该药物的商业化进程，并为上皮样肉瘤患者群体中存在的未满足临床需求提供潜在解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650188818","title":"港股異動 | 維立志博-B(09887.HK)升逾5% 維利信™獲納入優先審評審批程序 用於治療晚期肺外神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650188818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650188818?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 15:38","pubTimestamp":1783669103,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000500386.USD","09887","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901516","title":"維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲納入優先審評審批程序用於治療晚期肺外神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901516","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901516?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 12:32","pubTimestamp":1783657957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，维利信单药治疗晚期肺外神经内分泌癌的生物制品上市许可申请，已获中华人民共和国国家药品监督管理局药品审评中心批准纳入优先审评审批程序。根据相关中国法规，获纳入优先审评审批程序的BLA审评时限为130个工作日，而常规审评程序则为200个工作日。维利信获纳入优先审评程序标志着其迈向商业化的重要里程碑，为其预期获批时间表提供了明确指引及确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1169589451.USD","09887","LU1169590202.USD","HK0000252152.HKD","HK0000252160.HKD","BK4023","HK0000500386.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134216700","title":"維立志博-B獲NMPA優先審評資格　PD-L1/4-1BB雙抗維利信™衝刺EP-NEC首款上市藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=1134216700","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134216700?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 12:31","pubTimestamp":1783657890,"startTime":"0","endTime":"0","summary":"2026年7月10日，维立志博-B公布，其自主研发的PD-L1/4-1BB双特异性抗体奥帕替苏米单抗单药用于治疗晚期肺外神经内分泌癌的生物制品上市许可申请，获国家药品监督管理局药品审评中心纳入优先审评审批程序。根据中国现行法规，优先审评BLA的审评时限为130个工作日，较常规200个工作日显著缩短。公司提醒投资者，依据香港联交所证券上市规则第18A.05条，维利信仍处于监管审评阶段，无法保证最终能成功上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":106,"code":"91000000","status":"200"}]}}